Filing Details

Accession Number:
0001062993-23-019470
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-10-17 16:53:58
Reporting Period:
2023-10-16
Accepted Time:
2023-10-17 16:53:58
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1805387 Cerevel Therapeutics Holdings Inc. CERE () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1164426 Joseph Edelman 51 Astor Place, 10Th Floor
New York NY 10003
Yes No No No
1224962 Perceptive Advisors Llc 51 Astor Place, 10Th Floor
New York NY 10003
Yes No No No
1249675 Ltd Fund Master Sciences Life Perceptive 51 Astor Place, 10Th Floor
New York NY 10003
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-10-16 876,808 $22.81 10,794,876 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 170,317 Indirect See Footnote
Footnotes
  1. Includes 3,406,341 shares of common stock the Master Fund (as defined below) received pursuant to a liquidation distribution by ARYA Sciences Holdings II on April 11, 2023 (the "Liquidation Distribution").
  2. The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Mr. Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
  3. Represents 170,317 shares of common stock received by Mr. Edelman on April 11, 2023 pursuant to a distribution by Perceptive SP(A), L.P. (the "Co-Investment Fund") which the Co-Investment Fund received pursuant to the Liquidation Distribution.
  4. The securities are directly held by C2 Life Sciences, LLC ("C2"). The Advisor serves as the investment manager of C2 and Mr. Edelman is the managing member of the Advisor.